(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 March 2010 (11.03.2010)

PCT

(10) International Publication Number
WO 2010/026526 A1

(51) International Patent Classification:
A61K 31/4409 (2006.01) *A61K 31/5377* (2006.01)
A61K 31/4709 (2006.01) *A61K 31/541* (2006.01)
A61K 31/496 (2006.01) *A61K 45/06* (2006.01)
A61K 31/4965 (2006.01) *A61P 31/06* (2006.01)

(21) International Application Number:
PCT/IB2009/053796

(22) International Filing Date:
31 August 2009 (31.08.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/093,879 3 September 2008 (03.09.2008) US

(71) Applicants *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US). **THE JOHNS HOPKINS UNIVERSITY** [US/US]; 3400 N. Charles Street, Baltimore, Maryland 21218 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BRICKNER, Steven Joseph** [US/US]; 9 Fargo Drive, Ledyard, Connecticut 06339 (US). **NUERMBERGER, Eric** [US/US]; 1550 Orleans Street, Rm. 108, Baltimore, Maryland 21231 (US). **STOVER, Charles Kendall** [US/US]; 734 Turtle Pond Lane, Gaithersburg, Maryland 20878 (US).

(74) Agent: **BENSON, Gregg C.**; c/o Pfizer Inc. Eastern Point Road MS9114, Groton, Connecticut 06340 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

WO 2010/026526 A1

(54) Title: COMBINATION THERAPY FOR TUBERCULOSIS

(57) Abstract: The present invention relates to methods of treating tuberculosis, including multi¬ drug resistant varieties and latent tuberculosis. More particularly, the present invention relates to a method of treating tuberculosis in a mammal comprising administering to said mammal in need thereof an effective amount of a compound of formula (I), (S)-N- [[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, or a pharmaceutically acceptable salt thereof in combination with at least two agents useful in the treatment of tuberculosis. The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, (ii) a therapeutically effective amount of at least one agent useful in the treatment of tuberculosis and (iii) one or more pharmaceutically acceptable carriers or vehicles.